Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
additional information
-
tPA can act as a cytokine, executing its cytoprotective actions via activation of a survival signaling hierarchy in interstitial fibroblasts
diagnostics
-
alterations in tPA activity levels can be used as a biomarker for perturbations in brain homeostasis
diagnostics
-
alterations in tPA activity levels can be used as a biomarker for perturbations in brain homeostasis
-
drug development
-
antifibrinolytic agents may be useful for protecting neurons when tPA-mediated damage is anticipated
drug development
-
both TPA-antibiotic locks and heparin-antibiotic locks used in conjunction with systemic antibiotics can effectively clear catheter-related bacteraemia in children without significant late recurrence at 6 weeks. The mean infection-free survival of the catheters following TPA-antibiotic locks treatment is shorter than that following heparinantibiotic locks treatment, but is not statistically significant
drug development
-
neutrophils are good candidates to be the main source of metalloproteinase-9 following t-PA stroke treatment and in consequence, are partially responsible for thrombolysis-related brain bleedings. Combined therapy of t-PA with a metalloproteinase-9 or a neutrophil degranulation inhibitor may improve safety and efficacy of thrombolytic therapy in the acute phase of stroke
medicine
-
t-PA has been widely and successfully used as a therapeutic fibrinolytic agent to treat acute myocardial infarction and pulmonary embolism
medicine
-
non-glycosylated TK1-2 useful for the treatment of cancer can be efficiently produced in Pichia, with retaining its activity
medicine
the kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth by suppression of angiogenesis without interfering with fibrinolysis
medicine
-
combining antithrombin III, R-TPA and supportive care is more advantageous in treating the clinical manifestations of disseminated intravascular coagulation in this neonatal pig model than either single modality or supportive care alone
medicine
-
dogs with femoral artery thrombosis are given either M5, a single site mutant of prourkinase or tPA by i.v. infusion. Thrombolysis is comparably effective by both activators. Blood loss is 10-fold higher with t-PA than with M5 and occurred at more multiple sites. This effect is postulated to be related to differences in the mechanism of plasminogen activation by t-PA and M5 in which the latter is promoted by degraded rather than intact (hemostatic) fibrin
medicine
-
effects of intravenous administration of tPA on serum levels of IGF-1 and IGF-binding protein-3 in patients with acute ischemic stroke are investigated by radioimmunoassay in 10 patients. During tPA treatment, total IGF-1 and IGFBP-3 serum levels do not change, but there was an 70% increase in free IGF-1 serum levels at the end of the 1-h infusion. Intravenous therapy with tPA enhances the bioavailability of IGF-1
medicine
-
establishment of a global assay of overall haemostasis potential: coagulation cascade in platelet-poor plasma is triggered by adding a minimal dose of recombinant tissue factor together with purified phospholipids and calcium; fibrinolysis is initiated by adding recombinant tPA in a concentration similar to what can be obtained during thrombolysis. Numerical differentials of optical densities reflecting rates of fibrin formation and degradation are calculated, and the Coagulation Profile (Cp) and the Fibrinolysis Profile (Fp) are determined. The combined effect of these counteractive systems is expressed as a ratio of Cp to Fp, called the Overall Haemostasis Index
medicine
-
it is shown that exogenous tPA or tPA/plasminogen promotes axonal regeneration, remyelination, and functional recovery after sciatic nerve injury in the mouse, probably through removal of fibrin deposition and activation of MMP-9-positive macrophages, which may be responsible for myelin debris clearance and preventing collagen scar formation. Therefore, tPA may be useful for treatment of peripheral nerve injury
medicine
-
medical case report of a 14-year-old male with Down syndrome and acute myeloblastic leukemia, diagnosed with infective endocarditis characterized by two large vegetations on aortic and mitral valves, who is successfully treated with r-tPA
medicine
-
the present data support a model in which amyloid deposition in Alzheimer's disease induces a decrease in tPA activity through the overproduction of PAI-1 by activated glial cells
medicine
-
the present data support a model in which amyloid deposition in Alzheimer's disease induces a decrease in tPA activity through the overproduction of PAI-1 by activated glial cells
medicine
-
thromboelastography shows the clots formed from procine whole blood to be highly resistant to human tPA-catalyzed lysis, indicating a poor activation of porcine plasminogen by human rtPA. The results suggest caution in using the pig as an experimental model when studying the effects of various agents on fibrolysis
medicine
-
although rtPA enhances ischemic damage, the dose of recombinant tPA used in clinics does not affect the powerful neuroprotection by the JNK inhibitor XG-102
medicine
-
desmoteplase has additional advantages to human tPA, it is not neurotoxic and is unaffected by beta-amyloid. Desmoteplase antagonizes the neurotoxicity induced by vascular tPA possibly by competing with tPA for the low-density lipoprotein receptorrelated protein-1 binding at the BBB and thus preventing tPA access to the brain parenchyma. A phase III clinical trial of desmoteplase is halted since it has failed to demonstrate any beneficial effects in terms of neurological improvements and survival
medicine
-
excellent outcome (remarkable recovery 6 h after onset of symptoms) after the use of intravenous t-PA approximately 4 h after onset of symptoms for vertebrobasilar stroke
medicine
-
in comparison with t-PA, plasmin shows a distinct benefit-to-risk advantage. Plasmin is equally effective as t-PA in thrombolysis and may be superior for treating thrombi in totally-occluded vessels. Whereas t-PA causes bleeding from vascular trauma sites in animals when infused at dosages used for thrombolysis (0.5-1 mg/kg), plasmin exhibits safety at therapeutic dosages. Plasmin can be used at several fold higher concentrations than is needed for thrombolysis, thereby providing a significant safety margin that is not attainable for t-PA
medicine
-
ischemic stroke patients weighing more than 100 kg seem to derive less benefit from IV t-PA than their lighter counterparts
medicine
-
no evidence of hemorrhage or any adverse effect due to topical application of t-PA. Control and t-PA treated rats show fibrosis inhibition 6 weeks after surgery and show no significant difference in inflammation or with regard to necrosis and abscess formation
medicine
-
plasmin is a suitable alternative to t-PA as it causes less bleeding but has equivalent or greater thrombolytic efficacy
medicine
-
pregnancy is associated with major perturbations of endogenous fibrinolytic capacity with an overwhelming increase in plasma plasminogen activator inhibitor type 1 concentrations and an inadequate release of active t-PA, i.e., these prothrombotic effects may, in part, explain the increased risk of arterial and venous thrombosis in pregnant women
medicine
-
t-PA therapy has a clinically important and statistically significant benefit in spite of subgroup imbalances in baseline stroke severity and an increased risk of symptomatic intracerebral hemorrhage in patients receiving t-PA
medicine
-
tPA generation in wound epidermis is at least partially controlled by changes in local interleukin-1alpha activity
medicine
-
tPA is used as a thrombolytic agent for treatment of ischemic stroke and is the only agent that has been shown to improve stroke outcome in clinical trials. Patients receive little or no benefit if tPA therapy is initiated more than 3 h after the onset of stroke, which excludes most stroke patients from tPA treatment due to the time required for transportation to medical facilities and proper diagnosis. tPA may damage the basal lamina of the blood vessels, resulting in edema, disruption of the blood-brain barrier, or hemorrhage, thus any patients with evidence of hemorrhage or who have been taking any anti-coagulant medication such as aspirin are not candidates for tPA therapy
medicine
-
tPA-plasmin pathway dysfunction may play a role in the link between major depressive disorder and cardiovascular disease. Agents that modulate tPA-plasminogen activity may be potential drugs for the treatment of patients with both major depressive disorder and cardiovascular disease
medicine
-
tPA-plasmin pathway dysfunction may play a role in the link between major depressive disorder and cardiovascular disease. Agents that modulate tPA-plasminogen activity may be potential drugs for the treatment of patients with both major depressive disorder and cardiovascular disease
medicine
-
type 2 diabetes mellitus patients with periodontal disease and otherwise healthy periodontally diseased patients tend to exhibit higher total amounts of t-PA than systemically and periodontally healthy control subjects, thus type 2 diabetes seems not to increase gingival crevicular fluid levels of inflammatory mediators like t-PA
medicine
-
vaccination with a nucleoprotein with a tPA signal sequence efficiently clears homologous H5N1 influenza virus in infected lungs and induces partial cross-protection against heterologous, highly pathogenic H5N1 strains in mice. IFN-gamma producing T cells are more efficiently induced and expanded in mice immunized with ptPAs/nucleoprotein vaccine
medicine
-
working strategy for targeted delivery of recombinant tPA bound to magnetic nanoparticles with less than 20% of a regular dose under magnetic guidance, resulting in effective thrombolysis and restore of hemodynamics in the rat embolic model
medicine
-
enzyme has important thrombolytic properties due to its high fibrin affinity, it is approved for treating acute myocardial infarction, or heart attacks, and later for acute ischemic stroke, and acute, massive pulmonary embolism
medicine
-
in the rabbit small clot embolic stroke model, which is a useful translational model and possibly a predictor of treatments that may show efficacy in human clinical trials, in combination with the thrombolytic, tissue plasminogen activator using a standard intravenous dose of 3.3 mg/kg (20% bolus, 80% infused), simvastatin can be safely administered with tissue plasminogen activator to improve clinical scores
medicine
-
it is used clinically to dissolve
medicine
-
therapy for acute ischemic stroke
medicine
therapy for acute ischemic stroke
medicine
-
tissue plasminogen activator is the first-line treatment for stroke patients
medicine
-
putative interaction and cleavage of NR1 subunit of N-methyl-D-aspartate receptors by a tPA-dependent mechanism can be a relevant therapeutic target for stroke treatment in humans
medicine
-
the kringle 2 plus serine protease domains, K2S, of human tissue plasminogen activator is an efficacious thrombolytic drug, which is used to treat heart attacks and strokes by breaking up the fibrin clots that cause them
medicine
recombinant human t-PA is extensively used as a therapeutic agent for the treatment of thrombotic diseases owing to its greater safety and efficiency compared with other plasminogen activators like urokinase and streptokinase. CERTS132A-based secretion engineering can be an effective strategy for enhancing recombinant enzyme production in CHO cells
medicine
intensive care medication of ischemic stroke, thrombus targeting nanosystems could serve as carriers for enhanced delivery of enzyme tPA to the thrombi in order to increase its effective local concentrations. Biocompatible magnetite drug carriers, stabilized by a dextran shell, are developed to carry tissue plasminogen activator (tPA) for targeted thrombolysis under an external magnetic field, method evaluation, overview. Superparamagnetic iron oxide nanoparticles (SPIONs) have attracted great attention in many biomedical fields and are used in preclinical/experimental drug delivery, hyperthermia and medical imaging. All synthesized types of nanoparticles are well tolerated in cell culture experiments with human umbilical vein endothelial cells, indicating their potential utility for future therapeutic applications in thromboembolic diseases
medicine
tissue plasminogen activator converts plasminogen into plasmin and is used clinically to treat thrombosis
medicine
-
putative interaction and cleavage of NR1 subunit of N-methyl-D-aspartate receptors by a tPA-dependent mechanism can be a relevant therapeutic target for stroke treatment in humans
-